Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Natural Killer/T-cell Lymphoma × cemiplimab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Mycosis Fungoides 3 Recurrence 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Follicular 2 Lymphoma, B-Cell 2 Lymphoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Natural Killer/T-cell Lymphoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Myeloid, Acute 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Glioma 1 Glioblastoma 1 Carcinoma in Situ 1

Interventions

isatuximab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04763616 2021-09-24

ICING

Samsung Medical Center

Phase 2 Recruiting

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡